Medios AG continues dynamic growth in fiscal year 2016

Medios AG continues dynamic growth in fiscal year 2016

- Exceeded sales forecasts

- Strong growth thanks to heavy demand for personalized medicine

Berlin, February 15, 2017 - Medios AG, an expert pharmaceutical partner and solution provider in the Specialty Pharma segment, experienced significant growth in fiscal year 2016 thanks to strong demand for personalized medicine. According to provisional consolidated calculations (pro forma, IFRS), the corporation's sales revenue rose by 78% to EUR 160.5 million compared to the prior year (PY EUR 90.1 million). This was higher than market expectations.

The operating result (EBIT) made disproportionate gains of 100.4% to EUR 5.67 million (PY EUR 2.83 million), thus improving profitability: The EBIT margin rose to 3.53 % (PY 3.14%).

"Fiscal year 2016 was outstanding for Medios. With a significant increase in sales, we exceeded market expectations. As a result, we were able to more than double our operating result. This enormous growth shows that demand for personalized medicine is rising at a rapid pace. As a partner for individual patient supply, we benefit from this development. Thanks to our subsidiaries, Medios Pharma and Medios Manufaktur, we can cover two key elements of the value-added chain. This puts us in an optimal position to reach our goal of becoming the leading provider of Specialty Pharma Solutions in Germany," says Matthias Gärtner, board member of Medios AG.

Both business divisions of Medios AG have contributed to the growth in both sales and result: The subsidiary Medios Pharma GmbH, which operates as a specialized wholesaler nationwide supplying pharmacies with drugs in such areas as oncology, autoimmunology, and infectious diseases, generated sales of EUR 127.5 million (PY EUR 58.2 million) and an EBIT of EUR 3.92 million (PY EUR 1.06 million) in fiscal year 2016 according to IFRS. The subsidiary Medios Manufaktur GmbH, which produces individual drugs for patients on behalf of pharmacies, generated sales of EUR 43.5 million (PY EUR 35.3 million) and an EBIT of EUR 2.34 million (PY EUR 2 million) in fiscal year 2016 according to IFRS.

In addition to successful operations in fiscal year 2016, a high point was the
economical re-formation of Medios AG as a result of contributing the two subsidiaries. Medios AG also had an IPO on the regulated market of the Frankfurt Stock Exchange (General Standard) through what is referred to as a reverse IPO in addition to the successful placement of a cash capital increase of EUR 19.3 million.

In early 2017, Medios AG announced the formation of a new subsidiary. Medios Digital GmbH will take on all software development activities of Medios AG and all other group companies in the future. It will provide development, consulting, and operational services in the field of information and system technology - with a focus on software development, software maintenance and software support. The goal of Medios is broad digitalization of the Specialty Pharma commercial business.

The 2016 Annual Report, including a forecast for fiscal year 2017, will be published in April 2017.
About Medios AG

Medios AG, along with its subsidiaries Medios Pharma GmbH and Medios Manufaktur GmbH, has positioned itself in the specialty pharma segment as the go-to source for expertise and solutions. It brings together individual market players in a network of cooperating partners. Our objective is to ensure that patients have optimum access to pharmaceutical drugs and to offer integrated solutions along the value-added chain to partners and customers. Specialty pharmaceutical drugs are medications for patients with rare and/or chronic illnesses (for example, certain cancer, autoimmune diseases, and infectious diseases) that require lengthy and expensive customised treatment.

Contact

Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg

Phone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.